SC
Stempoint Capital Portfolio holdings
AUM
$520M
1-Year Est. Return
281.95%
This Fund
S&P 500
1 Year Est. Return
+281.95%
AUM
$520M
AUM Growth
-$62.4M
(-11%)
Holding
112
Top Buys
| 1 | +$22.2M | |
| 2 | +$17.4M | |
| 3 | +$14.3M | |
| 4 |
CG Oncology
CGON
|
+$11.7M |
| 5 |
Praxis Precision Medicines
PRAX
|
+$10.9M |
Top Sells
| 1 | +$28.9M | |
| 2 | +$21.7M | |
| 3 | +$21.3M | |
| 4 |
TERN
Terns Pharmaceuticals
TERN
|
+$17.6M |
| 5 |
Roivant Sciences
ROIV
|
+$14.9M |
Sector Composition
| 1 | Healthcare | 99.4% |
| 2 | Financials | 0.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Scholar Rock
SRRK
$5.35B
| $50.9M | 9.78% |
1,035,496
+148,603
|
|
||
|
ABVX
2
Abivax
ABVX
$5.78B
| $34.9M | 6.72% |
313,791
-77,992
|
|
||
3
Syndax Pharmaceuticals
SNDX
$1.63B
| $28.4M | 5.46% |
1,215,743
-123,636
|
|
||
4
Revolution Medicines
RVMD
$32.2B
| $27.4M | 5.26% |
281,632
+219,600
|
|
||
5
Immunovant
IMVT
$6.35B
| $18.5M | 3.56% |
746,494
+101,535
|
|
||
|
6
Praxis Precision Medicines
PRAX
$7.19B
| $18.1M | 3.48% |
56,267
+35,200
|
|
||
|
MBX
7
MBX Biosciences
MBX
$1.46B
| $14.9M | 2.87% |
499,469
+420,916
|
|
||
8
Mineralys Therapeutics
MLYS
$2.38B
| $14.4M | 2.78% |
533,378
+243,329
|
|
||
9
Enliven Therapeutics
ELVN
$2.16B
| $14.2M | 2.74% |
+363,438
|
|
||
|
10
CG Oncology
CGON
$4.9B
| $13.9M | 2.68% |
+205,622
|
|
||
11
Biohaven
BHVN
$1.53B
| $13.5M | 2.59% |
+1,594,491
|
|
||
12
Surrozen
SRZN
$269M
| $13.5M | 2.59% |
525,639
-94,127
|
|
||
|
13
Roivant Sciences
ROIV
$20.3B
| $10.7M | 2.05% |
385,800
-580,898
|
|
||
14
EyePoint Inc
EYPT
$1.05B
| $10.5M | 2.01% |
810,764
+456,915
|
|
||
15
Arcutis Biotherapeutics
ARQT
$2.6B
| $9.75M | 1.87% |
413,792
+189,052
|
|
||
16
Structure Therapeutics
GPCR
$2.64B
| $9.65M | 1.86% |
200,267
-150,806
|
|
||
17
Amylyx Pharmaceuticals
AMLX
$1.48B
| $9.31M | 1.79% |
669,685
+104,545
|
|
||
18
Dyne Therapeutics
DYN
$2.85B
| $9.18M | 1.76% |
506,075
-329,125
|
|
||
19
Edgewise Therapeutics
EWTX
$4.01B
| $9.16M | 1.76% |
290,864
-70,012
|
|
||
20
Cytokinetics
CYTK
$9.63B
| $8.54M | 1.64% |
129,577
-17,401
|
|
||
21
Spyre Therapeutics
SYRE
$6.01B
| $8.45M | 1.63% |
167,606
+135,229
|
|
||
22
Denali Therapeutics
DNLI
$3.07B
| $8.19M | 1.57% |
426,561
+7,503
|
|
||
23
Xenon Pharmaceuticals
XENE
$5.06B
| $8.18M | 1.57% |
140,755
-207,850
|
|
||
24
Celldex Therapeutics
CLDX
$2.27B
| $8.07M | 1.55% |
+254,267
|
|
||
25
Protagonist Therapeutics
PTGX
$6B
| $7.65M | 1.47% |
72,577
+13,147
|
|